Divergent roles of serum CXCL9 as a biomarker in ILD and COPD: a comparative study
Open Access
- 3 February 2026
- journal article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17
Abstract
Background: The chemokine CXCL9, induced by interferon-γ (IFN-γ), is a hallmark of type 1 (T1) inflammation. Its role in chronic respiratory diseases remains unclear, with conflicting evidence suggesting it may reflect steroid-responsive inflammation in interstitial lung disease (ILD) but correlate with worse function in chronic obstructive pulmonary disease (COPD). Methods: Serum levels of CXCL9, KL-6, SP-A, and CRP were measured in 83 ILD patients (with paired samples before and after treatment), 94 COPD patients, and 100 healthy controls (50 smokers and 50 non-smokers). Lung function and biomarker correlations were analyzed, and unsupervised cluster analysis was used to explore inflammatory phenotypes. Results: CXCL9 levels were markedly elevated in both ILD (median: 57.4 pg/mL) and COPD (70.1 pg/mL) compared to healthy smokers (32.5 pg/mL) and non-smokers (37.0 pg/mL). In COPD, CXCL9 correlated with KL-6 (r = 0.459) and SP-A (r = 0.274), indicating neutrophilic inflammation and epithelial injury. In ILD, higher baseline CXCL9 levels predicted subsequent improvement in lung function and declined following treatment. Cluster analysis revealed divergent CXCL9 and KL-6 trajectories linked to disease outcomes, underscoring their value as dynamic, disease-specific biomarkers. Conclusion: CXCL9 levels correlate with divergent roles in ILD and COPD. It may serve as a prognostic marker, identifying treatable inflammation in ILD and inflammatory burden in COPD.Keywords
This publication has 33 references indexed in Scilit:
- Identifying chronic obstructive pulmonary disease subtypes using multi-trait geneticsEBioMedicine, 2025
- The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPDChest, 2024
- Long-term risks of respiratory diseases in patients infected with SARS-CoV-2: a longitudinal, population-based cohort studyeClinicalMedicine, 2024
- Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD SpectrumThe Journal of Allergy and Clinical Immunology: In Practice, 2023
- Development of a new HISCL automated CXCL9 immunoassayScientific Reports, 2023
- Type 1 inflammatory endotype relates to low compliance, lung fibrosis, and severe complications in COVID-19Cytokine, 2021
- Dyspnea, Elevated Jugular Venous Pulse, and Lower Extremity Edema in the Setting of Interstitial Lung Disease in a Patient Who Has Undergone Liver and Kidney TransplantationChest, 2021
- Serum CXCL9 as a potential marker of Type 1 inflammation in the context of eosinophilic asthmaAllergy, 2019
- Surfactant proteins A and D: disease markersBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1998
- Detection of Interstitial Pneumonitis in Patients with Rheumatoid Arthritis by Measuring Circulating Levels of KL-6, a Human MUC1 MucinLung, 1997